Summary:
Buy
| Technical Indicators: | Buy |
| Moving Averages: | Strong Buy |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -40.01 | |||
ROE last 12 Months | -0.27 | |||
ROA (5Y Avg) | -5.09 | |||
ROA last 12 Months | -0.11 | |||
ROC (5Y Avg) | -45.64 | |||
ROC last 12 Months | 3.01 | |||
Return on invested Capital Q | -3.10 | |||
Return on invested Capital Y | 8.35 | |||
Assets Turnover | 0.30 | |||
Receivables Turnover | 3.90 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 18.90 | ||||
| 1.38 | ||||
| 3.84 | ||||
| 4.30 | ||||
| -27.40 | ||||
| 1.63 | ||||
| -2.49 | ||||
| 5.07 | ||||
| 577.34M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.90 | ||||
| 1.60 | ||||
| 0.40 | ||||
| 0.66 | ||||
| 1.00 | ||||
| Leverage Ratio | 2.30 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 47.60 | ||||
| 10.70 | ||||
| 36.30 | ||||
| -92.20 | ||||
| -22.42 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 241.60M | ||||
| 3.78 | ||||
| 100.09 | ||||
| 197.73 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2022 | -0.04 | -0.06 | -50.00 |
| Q02 2022 | -0.04 | -0.02 | 50.00 |
| Q01 2022 | -0.05 | -0.05 | 0.00 |
| Q04 2021 | -0.14 | 0.15 | 207.14 |
| Q03 2021 | -0.21 | -0.07 | 66.67 |
| Q02 2021 | -0.09 | -0.04 | 55.56 |
| Q01 2021 | - | -0.09 | - |
| Q03 2020 | - | -0.07 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 0 |
| Shares Outstanding | 0 |
| Shares Float | 0 |
| Trades Count | 0 |
| Dollar Volume | 0 |
| Avg. Volume | 0 |
| Avg. Weekly Volume | 0 |
| Avg. Monthly Volume | 0 |
| Avg. Quarterly Volume | 0 |
Amryt Pharma plc (NASDAQ: AMYT) stock closed at 14.7 per share at the end of the most recent trading day (a 0.07% change compared to the prior day closing price) with a volume of 2.38M shares and market capitalization of 0.0000. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 88 people. Amryt Pharma plc CEO is Joseph Amrit Wiley.
The one-year performance of Amryt Pharma plc stock is %, while year-to-date (YTD) performance is 101.37%. AMYT stock has a five-year performance of %. Its 52-week range is between and , which gives AMYT stock a 52-week price range ratio of %
Amryt Pharma plc currently has a PE ratio of 18.90, a price-to-book (PB) ratio of 1.38, a price-to-sale (PS) ratio of 3.84, a price to cashflow ratio of 4.30, a PEG ratio of 2.32, a ROA of -0.11%, a ROC of 3.01% and a ROE of -0.27%. The company’s profit margin is -22.42%, its EBITDA margin is 36.30%, and its revenue ttm is $241.60 Million , which makes it $3.78 revenue per share.
Of the last four earnings reports from Amryt Pharma plc, there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Amryt Pharma plc’s next earnings report date is -.
The consensus rating of Wall Street analysts for Amryt Pharma plc is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Amryt Pharma plc stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Amryt Pharma plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Amryt Pharma plc has a Buy technical analysis rating based on Technical Indicators (ADX : 17.39, ATR14 : 0.06, CCI20 : 264.51, Chaikin Money Flow : 0.07, MACD : 0.07, Money Flow Index : 71.36, ROC : 1.03, RSI : 69.19, STOCH (14,3) : 71.43, STOCH RSI : 1.00, UO : 59.41, Williams %R : -28.57), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Amryt Pharma plc in the last 12-months were:
Amryt Pharma plc
Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).
CEO: Joseph Amrit Wiley
Telephone: +44 2030267257
Address: 196 High Road, London N22 8HH, , GB
Number of employees: 88
